甘李

英文版仅为中文版之翻译，若中英歧义，请以中文版为准。
The English translation is for reference purposes only.
In the event of any discrepancy between the Chinese original and the English translation, the Chinese original shall prevail.



2026
第三季度报告
The Third Quarter Report in 2026

甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

重要内容提示
Important Notes 3

一、主要财务数据
I Major Financial Data 4

二、股东信息
II Shareholder Information 9

三、季度财务报表
III Quarterly Financial Statements 13

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真实、准确、完整。

第三季度财务报表是否经审计

否

Important Notes:

The Board of Directors, the Supervisory Committee and directors, supervisors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

The legal representative, chief accountant, and head of accounting department (accounting supervisor) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the third quarter financial statements are audited

No

主要财务数据
Major Financial Data



一、主要财务数据 I Major Financial Data

(一) 主要会计数据和财务指标 (I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Item	本报告期 Current reporting period	本报告期比上年同期增减变动幅度(%) Change in the current reporting period over the same period of the previous year (%)	年初至报告期末 Beginning of the year to the end of the reporting period	年初至报告期末比上年同期增减变动幅度(%) Change from the beginning of the year to the end of the reporting period over the same period of the previous year (%)
营业收入 Operating income	1,146,023,434.40	16.91	3,369,045,274.87	10.57
利润总额 Total profit	289,060,638.87	23.17	976,163,380.28	5.45
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	248,304,903.01	15.67	858,085,433.36	4.86
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	236,564,512.33	15.67	816,768,908.79	17.96
经营活动产生的现金流量净额 Net cash flows from operating activities	不适用 N/A	不适用 N/A	663,466,744.55	37.66
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.42	16.67	1.45	5.07
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.42	16.67	1.45	5.07
加权平均净资产收益率(%) Weighted average return on net assets (%)	2.11	增加0.19个百分点 Increase by 0.19 percentage points	7.25	增加0.04个百分点 Increase by 0.04 percentage points

	本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增减变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total Assets	13,678,834,078.60	12,627,043,306.54	8.33
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company	11,977,093,559.82	11,628,469,164.23	3.00

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: "Current reporting period" refers to the three-month period from beginning to end of the current quarter, and the same applies hereinafter.

（二） 非经常性损益项目和金额 (II) Items and amounts of non-recurring gains and losses

单位：元 币种：人民币
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period	年初至报告期末金额 Amount from the beginning of the year to the end of the reporting period	说明 Note
非流动性资产处置损益，包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions	-85,891.73	-320,680.28	
计入当期损益的政府补助，但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the Company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	1,937,800.52	8,044,911.05	
除同公司正常经营业务相关的有效套期保值业务外，非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	14,603,202.67	28,934,783.51	
处置长期股权投资产生的投资收益	Investment income arising from the disposal of long term equity investments		3,017,916.14	
丧失控制权后，剩余股权按公允价值重新计量产生的利得	Gains arising from the remeasurement of the remaining equity interests at fair value after loss of control		2,541,161.06	
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	-2,490,538.88	-5,574,893.47	
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses		11,900,000.00	
减：所得税影响额	Less: Amount affected by income tax	2,224,181.90	7,226,673.44	
合计	Total	11,740,390.68	41,316,524.57	

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "*Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses*" and the amount of which is material, as well as items defined as non-recurring gains and losses in "*Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses*", the reasons shall be explained.

单位：元 币种：人民币
Unit: RMB

项目 Item	涉及金额 Amount	原因 Reason
递延收益的摊销 Amortization of deferred income	10,623,343.78	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses

(三) 主要会计数据、财务指标发生变动的情况、原因

(III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称	Item	变动比例(%) Percentage of change (%)	主要原因	Main reason
经营活动产生的现金流量净额_年初至报告期末	Net cash flows from operating activities_from the beginning of the year to the end of the reporting period	37.66	见表格下方说明。	See note below the table.

说明：
经营活动产生的现金流量净额_年初至报告期末变动原因：

Note:
Reasons for Changes in Net Cash Flows Generated from Operating Activities for the Period from the Beginning of the Year to the End of the Reporting Period:

2026年前三季度经营活动产生的现金流量净额为6.63亿元，同比增长37.66%，主要系年初至报告期末销售商品、提供劳务收到的现金增加所致。销售商品、提供劳务收到的现金增加，主要为公司营业收入增长所致。

In the first three quarters of 2026, the Company's net cash flows generated from operating activities amounted to RMB663 million, representing a year-on-year increase of 37.66%, primarily attributable to the increase in cash received from sales of goods and provision of services during the period from the beginning of the year to the end of the reporting period. The increase in cash received from sales of goods and provision of services was primarily due to the growth in the Company's operating revenue.

2026年前三季度，公司实现营业收入33.69亿元，较上年同期增长10.57%；胰岛素制剂产品销量为9,059万支，较上年同期增长24.23%。具体情况如下：

In the first three quarters of 2026, the Company achieved operating revenue of RMB3.369 billion, representing a year-on-year increase of 10.57%; the sales volume of insulin preparation products was 90.59 million units, representing a year-on-year increase of 24.23%. Details are as follows:

(1)国内收入

2026年前三季度，公司国内收入27.97亿元，较上年同期增长1.06亿元，同比增长3.96%，主要系胰岛素制剂产品销量增加。

(I)Domestic Revenue

In the first three quarters of 2026, the Company's domestic revenue amounted to RMB2.797 billion, an increase of RMB106 million, or 3.96%, compared with the same period of the previous year, primarily attributable to the increase in sales volume of insulin preparation products.

(2)国际收入

2026年前三季度，公司国际收入为5.72亿元，较上年同期增加2.16亿元，同比增长60.38%，国际销售收入和国际特许权服务收入均大幅增加。国际收入增长主要来源于以下两个方面：

(II)International Revenue

In the first three quarters of 2026, the Company's international revenue amounted to RMB572 million, an increase of RMB216 million, or 60.38%, compared with the same period of the previous year, with both international sales revenue and international licensing service revenue increasing significantly. The growth in international revenue was primarily attributable to the following two aspects:

①国际销售收入。2026年前三季度，国际销售收入为4.74亿元，较上年同期增加1.21亿元，同比增长34.36%，主要系公司与巴西合作伙伴共同推进的PDP项目产品供货有序开展，本报告期该项目贡献收入1.83亿元。

① International Sales Revenue. In the first three quarters of 2026, international sales revenue amounted to RMB474 million, an increase of RMB121 million, or 34.36%, compared with the same period of the previous year, primarily attributable to the orderly implementation of product supply under the PDP project jointly advanced by the Company and its Brazilian partner, which contributed revenue of RMB183 million during the reporting period.

②国际特许权服务收入。2026年前三季度，国际特许权服务收入较上年同期增加0.94亿元，主要系公司围绕核心创新产品持续推进全球授权合作，已与拉美、印度、韩国等市场的头部药企就博凡格鲁肽注射液达成独家许可协议，并按照协议约定确认特许权服务收入所致。

② International Licensing Service Revenue. In the first three quarters of 2026, international licensing service revenue increased by RMB94 million compared with the same period of the previous year, primarily attributable to the Company's continued advancement of global licensing cooperation in respect of its core innovative products, pursuant to which the Company entered into exclusive licensing agreements with leading pharmaceutical companies in markets such as Latin America, India and South Korea for Bofanglutide Injection and recognized licensing service revenue in accordance with the terms of such agreements.

2026年8月，公司与欧洲领先的制药企业就博凡格鲁肽注射液的上市注册和商业化合作签署独家许可协议，并于2026年10月收到首付款6,200万欧元。

In August 2026, the Company entered into an exclusive licensing agreement with a leading European pharmaceutical company for the marketing authorization and commercialization of Bofanglutide Injection, and received an upfront payment of EUR 62 million in October 2026.

股东信息
Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

(I) Total number of ordinary shareholders, the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholding

单位：股
Unit: Share

报告期末普通股股东总数 Total number of ordinary shareholders at the end of the current reporting period	67,098	报告期末表决权恢复的优先股股东总数（如有） Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)	0

前10名股东持股情况（不含通过转融通出借股份）
Shareholdings of top ten shareholders (excluding shares lending through securities lending)

股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen	
					股份状态 Share status	数量 Number
甘忠如 Zhongru Gan	境内自然人 Domestic natural person	205,643,757	34.42	28,508,550	无 None	
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人 Domestic non-state-owned legal entity	32,073,734	5.37		质押 Pledged	8,570,000
基本养老保险基金八零二组合 Basic Pension Insurance Fund Portfolio No. 802	其他 Other	19,004,220	3.18		无 None	
全国社保基金一一三组合 National Social Security Fund Portfolio No. 113	其他 Other	18,614,962	3.12		无 None	
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金 Industrial and Commercial Bank of China Limited – China Europe Healthcare Hybrid Securities Investment Fund	其他 Other	6,034,681	1.01		无 None	
甘喜茹 Xiru Gan	境内自然人 Domestic natural person	6,000,000	1.00		质押 Pledged	310,000
上海银行股份有限公司－银华中证创新药产业交易型开放式指数证券投资基金 Shanghai Bank Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Fund	其他 Other	5,598,894	0.94		无 None	
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	其他 Other	5,403,177	0.90		无 None	

单位：股
Unit: Share

前10名股东持股情况（不含通过转融通出借股份）
Shareholdings of top ten shareholders (excluding shares lending through securities lending)

股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen	
					股份状态 Share status	数量 Number
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	其他 Other	5,009,900	0.84		无 None	
HH G&L Holdings (HK) Limited	境外法人 Overseas legal entity	4,296,032	0.72	4,296,032	无 None	

前10名无限售条件股东持股情况（不含通过转融通出借股份）
Shareholdings of the top ten shareholders with unlimited trading conditions(excluding shares lending through securities lending)

股东名称 Shareholder name	持有无限售条件流通股的数量 Number of unlimited shares outstanding	股份种类及数量 Category and number of shares	
		股份种类 Category	数量 Number
甘忠如 Zhongru Gan	177,135,207	人民币普通股 RMB ordinary shares	177,135,207
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd	32,073,734	人民币普通股 RMB ordinary shares	32,073,734
基本养老保险基金八零二组合 Basic Pension Insurance Fund Portfolio No. 802	19,004,220	人民币普通股 RMB ordinary shares	19,004,220
全国社保基金一一三组合 National Social Security Fund Portfolio No. 113	18,614,962	人民币普通股 RMB ordinary shares	18,614,962
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金 Industrial and Commercial Bank of China Limited – China Europe Healthcare Hybrid Securities Investment Fund	6,034,681	人民币普通股 RMB ordinary shares	6,034,681
甘喜茹 Xiru Gan	6,000,000	人民币普通股 RMB ordinary shares	6,000,000
上海银行股份有限公司－银华中证创新药产业交易型开放式指数证券投资基金 Shanghai Bank Co., Ltd. - Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Fund	5,598,894	人民币普通股 RMB ordinary shares	5,598,894
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	5,403,177	人民币普通股 RMB ordinary shares	5,403,177
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	5,009,900	人民币普通股 RMB ordinary shares	5,009,900

单位：股
Unit: Share

前10名无限售条件股东持股情况(不含通过转融通出借股份) Shareholdings of the top ten shareholders with unlimited trading conditions(excluding shares lending through securities lending)			
股东名称 Shareholder name	持有无限售条件流通股的数量 Number of unlimited shares outstanding	股份种类及数量 Category and number of shares	
		股份种类 Category	数量 Number
基本养老保险基金二零零二组合 Basic Pension Insurance Fund Portfolio No. 2002	3,792,275	人民币普通股 RMB ordinary shares	3,792,275
上述股东关联关系或一致行动的说明 Explanation of the above shareholders' affiliation or concerted action	公司控股股东、实际控制人甘忠如持有旭特宏达96.28%的股权；甘喜茹为甘忠如胞妹。除以上情况外，其他股东之间不存在关联关系或一致行动。 Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 96.28% of the shares of Beijing Xute Hongda Technology Co.,Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.		
前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有) Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)	不适用 N/A		

季度财务报表

Quarterly Financial Statements



三、季度财务报表 III Quarterly Financial Statements

(一) 财务报表 (I) Financial reports

合并资产负债表
Consolidated Balance Sheet

2026年9月30日
September 30, 2026

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type:Unaudited

项目	Item	2026年9月30日 September 30, 2026	2025年12月31日 December 31, 2025
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	1,729,967,613.89	2,088,313,116.28
交易性金融资产	Financial assets held for trading	2,529,277,560.90	1,401,114,684.93
应收票据	Notes receivable	12,039,778.34	6,078,174.99
应收账款	Accounts receivable	883,509,526.34	593,231,015.05
应收款项融资	Financing receivables	41,045,554.02	561,084.73
预付款项	Prepayments	88,284,892.23	55,480,540.46
其他应收款	Other receivables	7,295,892.68	3,759,148.34
存货	Inventories	1,192,319,610.48	1,008,687,851.59
一年内到期的非流动资产	Non-current assets due within one year	191,164,966.52	324,456,250.00
其他流动资产	Other current assets	36,326,113.97	2,387,272.78
流动资产合计	Total current assets	6,711,231,509.37	5,484,069,139.15
非流动资产:	Non-current Assets:		
债权投资	Debt investments		187,438,589.23
长期股权投资	Long-term equity investment	283,112,366.22	264,150,000.00
其他非流动金融资产	Other non-current financial assets	20,717,786.88	68,937,018.25
固定资产	Fixed assets	2,979,932,874.29	3,180,567,912.45
在建工程	Construction in progress	716,694,885.30	393,466,750.17
使用权资产	Right-of-use assets	2,755,957.43	3,412,247.56
无形资产	Intangible assets	606,677,589.74	265,113,204.04
开发支出	Development expenditures	1,784,078,637.84	1,611,487,766.42
长期待摊费用	Long-term deferred expenses		10,504.33
递延所得税资产	Deferred tax assets	163,546,381.31	213,669,657.49
其他非流动资产	Other non-current assets	410,086,090.22	954,720,517.45
非流动资产合计	Total non-current assets	6,967,602,569.23	7,142,974,167.39
资产总计	Total assets	13,678,834,078.60	12,627,043,306.54

合并资产负债表（续）
Consolidated Balance Sheet (Continued)

项目	Item	2026年9月30日 September 30, 2026	2025年12月31日 December 31, 2025
流动负债：	Current Liabilities		
应付账款	Accounts payable	249,083,196.46	134,407,798.36
合同负债	Contract liabilities	32,788,210.09	67,880,818.01
应付职工薪酬	Payroll and employee benefits payable	188,401,716.70	187,264,485.58
应交税费	Taxes payable	107,125,687.43	50,873,900.40
其他应付款	Other payables	265,582,222.24	360,327,524.24
一年内到期的非流动负债	Non-current liabilities due within one year	5,283,734.73	8,990,459.93
其他流动负债	Other current liabilities	396,178,914.60	6,041,815.11
流动负债合计	Total current liabilities	1,244,443,682.25	815,786,801.63
非流动负债：	Non-current Liabilities:		
长期借款	Long-term borrowings	228,081,225.17	
租赁负债	Lease liabilities	1,651,788.87	2,539,557.29
长期应付款	Long-term payables	2,677,512.46	9,501,468.09
递延收益	Deferred income	211,332,774.45	170,746,315.30
递延所得税负债	Deferred tax liabilities	13,553,535.58	
非流动负债合计	Total non-current liabilities	457,296,836.53	182,787,340.68
负债合计	Total liabilities	1,701,740,518.78	998,574,142.31
所有者权益（或股东权益）：	Owners' (or Shareholders') equity:		
实收资本（或股本）	Paid-in capital (or share capital)	597,432,169.00	597,304,969.00
资本公积	Capital reserve	3,573,112,190.99	3,533,621,701.64
减：库存股	Less: Treasury shares	61,623,290.00	111,168,980.00
其他综合收益	Other comprehensive income	1,240,823.12	3,063,071.24
盈余公积	Surplus reserve	300,532,645.00	300,532,645.00
未分配利润	Retained earnings	7,566,399,021.71	7,305,115,757.35
归属于母公司所有者权益（或股东权益）合计	Total owner's equity (or shareholders' equity) attributable to the parent company	11,977,093,559.82	11,628,469,164.23
所有者权益（或股东权益）合计	Total owners' (or shareholders') equity	11,977,093,559.82	11,628,469,164.23
负债和所有者权益（或股东权益）总计	Total liabilities and owners' (or Shareholders') equity	13,678,834,078.60	12,627,043,306.54

公司负责人：	陈伟	主管会计工作负责人：	王琦	会计机构负责人：	周丽
Legal Representative:	Wei Chen	Chief Accountant:	Qi Wang	Head of Accounting Department:	Li Zhou

合并利润表
Consolidated Income Statement

2026年1—9月
Jan. to Sept., 2026

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位：元 币种:人民币 审计类型：未经审计
Unit: RMB Audit type:Unaudited

项目	Item	2026年前三季度 First three quarters of 2026(Jan.to Sept.)	2025年前三季度 First three quarters of 2025(Jan. to Sept.)
一、营业总收入	I. Total operating Revenue	3,369,045,274.87	3,047,039,079.24
其中：营业收入	Of which: Operating income	3,369,045,274.87	3,047,039,079.24
二、营业总成本	II. Total operating costs	2,465,157,856.00	2,275,937,092.07
其中：营业成本	Of which: Operating costs	846,645,045.67	725,750,228.68
税金及附加	Taxes and surcharges	44,581,534.61	28,744,855.36
销售费用	Selling expenses	943,395,094.65	978,990,601.81
管理费用	General and administrative expenses	188,324,368.92	196,121,275.25
研发费用	R&D expenses	463,022,514.85	407,861,819.05
财务费用	Financial expenses	-20,810,702.70	-61,531,688.08
加：其他收益	Add: Other income	22,402,581.46	15,707,102.52
投资收益(损失以“-”号填列)	Investment income or loss (loss is indicated with "-")	32,778,859.69	10,823,936.85
公允价值变动收益(损失以“-”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	28,197,494.53	72,066,564.13
信用减值损失(损失以“-”号填列)	Credit impairment losses (loss is indicated with “-”)	2,212,854.03	-1,923,291.76
资产减值损失(损失以“-”号填列)	Assets impairment losses (loss is indicated with "-")	-6,441,800.92	876,940.21
资产处置收益(损失以“-”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")	-51,155.30	
三、营业利润(亏损以“-”号填列)	III. Operating Profit (loss is indicated with “-”)	982,986,252.36	868,653,239.12
加：营业外收入	Add: Non-operating income	1,638,385.87	62,344,001.18
减：营业外支出	Less: Non-operating expenses	8,461,257.95	5,287,205.22
四、利润总额(亏损总额以“-”号填列)	IV. Profit before tax (loss is indicated with "-")	976,163,380.28	925,710,035.08
减：所得税费用	Less: Income tax expense	118,523,202.53	107,370,417.78
五、净利润(净亏损以“-”号填列)	V. Net Profit (net loss is indicated with “-”)	857,640,177.75	818,339,617.30
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“-”号填列)	1. Net profit from continuing operations (loss is indicated with “-”)	857,640,177.75	818,339,617.30

合并利润表（续）
Consolidated Income Statement (Continued)

项目	Item	2026年前三季度 First three quarters of 2026(Jan.to Sept.)	2025年前三季度 First three quarters of 2025(Jan. to Sept.)
（二）按所有权归属分类	(II) Categorized by ownership		
1.归属于母公司股东的净利润（净亏损以“-”号填列）	1. Net profit attributable to owners of the parent company (net loss is indicated with "-")	858,085,433.36	818,339,617.30
2.少数股东损益（净亏损以“-”号填列）	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")	-445,255.61	
六、其他综合收益的税后净额	VI. Other comprehensive income net of tax	-1,822,248.12	-406,764.76
（一）归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	-1,822,248.12	-406,764.76
1．不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2．将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-1,822,248.12	-406,764.76
(1)外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-1,822,248.12	-406,764.76
（二）归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	855,817,929.63	817,932,852.54
（一）归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	856,263,185.24	817,932,852.54
（二）归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-445,255.61	
八、每股收益：	VIII. Earnings Per Share:		
（一）基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	1.45	1.38
（二）稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	1.45	1.38

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：	陈伟	主管会计工作负责人：	王琦	会计机构负责人：	周丽
Legal Representative:	Wei Chen	Chief Accountant:	Qi Wang	Head of Accounting Department:	Li Zhou

合并现金流量表
Consolidated Statement of Cash Flows

2026年1—9月
Jan.to Sept.,2026

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位：元 币种:人民币 审计类型：未经审计
Unit: RMB Audit type:Unaudited

项目	Item	2026年前三季度 First three quarters of 2026(Jan.to Sept.)	2025年前三季度 First three quarters of 2025(Jan. to Sept.)
一、经营活动产生的现金流量：	I. Cash Flows from Operating Activities:		
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	3,305,781,057.84	2,799,253,112.31
收到的税费返还	Tax refunds received	29,358,060.88	85,506,119.06
收到其他与经营活动有关的现金	Cash received relating to other operating activities	87,856,412.96	75,818,636.58
经营活动现金流入小计	Sub-total of cash inflows from operating activities	3,422,995,531.68	2,960,577,867.95
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	801,110,631.18	725,969,731.03
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	825,926,700.86	764,768,091.94
支付的各项税费	Cash paid for taxes	336,126,237.50	237,385,212.17
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	796,365,217.59	750,494,376.24
经营活动现金流出小计	Sub-total of cash outflows from operating activities	2,759,528,787.13	2,478,617,411.38
经营活动产生的现金流量净额	Net cash flows from operating activities	663,466,744.55	481,960,456.57
二、投资活动产生的现金流量：	II. Cash Flows from Investing Activities:		
收回投资收到的现金	Cash received from disposal of investment	8,184,997,600.00	4,862,623,970.00
取得投资收益收到的现金	Cash receipts from investment income	193,123,219.51	79,501,731.75
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets		18,056.00
投资活动现金流入小计	Sub-total of cash inflows from investing activities	8,378,120,819.51	4,942,143,757.75
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	1,032,290,879.72	627,863,920.32
投资支付的现金	Cash paid for investments	8,249,463,800.00	3,982,756,561.06

合并现金流量表（续）
Consolidated Statement of Cash Flows (Continued)

项目	Item	2026年前三季度 First three quarters of 2026(Jan.to Sept.)	2025年前三季度 First three quarters of 2025(Jan. to Sept.)
投资活动现金流出小计	Sub-total of cash outflows from investing activities	9,281,754,679.72	4,610,620,481.38
投资活动产生的现金流量净额	Net cash flows from investing activities	-903,633,860.21	331,523,276.37
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from investment absorption	22,239,138.83	
取得借款收到的现金	Cash received from borrowings	228,081,225.17	
收到其他与筹资活动有关的现金	Other cash received relating to financing activities	384,952,014.11	
筹资活动现金流入小计	Subtotal of cash inflows from financing activities	635,272,378.11	
分配股利、利润或偿付利息支付的现金	Cash paid for dividend and profit distribution or interest payment	597,591,058.48	597,197,899.00
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	7,570,361.55	140,071,249.60
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	605,161,420.03	737,269,148.60
筹资活动产生的现金流量净额	Net cash flow from financing activities	30,110,958.08	-737,269,148.60
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	-3,449,925.49	2,686,658.89
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	-213,506,083.07	78,901,243.23
加：期初现金及现金等价物余额	V. Net increase in cash and cash equivalents	343,707,442.68	260,055,136.76
六、期末现金及现金等价物余额	VI. Closing balance of cash and cash equivalents	130,201,359.61	338,956,379.99

公司负责人：	陈伟	主管会计工作负责人：	王琦	会计机构负责人：	周丽
Legal Representative:	Wei Chen	Chief Accountant:	Qi Wang	Head of Accounting Department:	Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会
The Board of Directors of Gan & Lee Pharmaceuticals.

2026年10月26日
October 26, 2026



甘李药业股份有限公司
地址：北京市通州区漷县镇南凤西一路8号
网址：http://www.ganlee.com
电话： +86 010-80593699
邮编： 101109